Suppr超能文献

乳腺癌耐药蛋白、多药耐药相关蛋白 2 和 P-糖蛋白活性调节剂的结合部位相互作用。

Binding Site Interactions of Modulators of Breast Cancer Resistance Protein, Multidrug Resistance-Associated Protein 2, and P-Glycoprotein Activity.

机构信息

Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, P.O. Box 56, Helsinki 00014, Finland.

Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, P.O. Box 56, Helsinki 00014, Finland.

出版信息

Mol Pharm. 2020 Jul 6;17(7):2398-2410. doi: 10.1021/acs.molpharmaceut.0c00155. Epub 2020 Jun 18.

Abstract

ATP-binding cassette (ABC)-transporters protect tissues by pumping their substrates out of the cells in many physiological barriers, such as the blood-brain barrier, intestine, liver, and kidney. These substrates include various endogenous metabolites, but, in addition, ABC transporters recognize a wide range of compounds, therefore affecting the disposition and elimination of clinically used drugs and their metabolites. Although numerous ABC-transporter inhibitors are known, the underlying mechanism of inhibition is not well characterized. The aim of this study is to deepen our understanding of transporter inhibition by studying the molecular basis of ligand recognition. In the current work, we compared the effect of 44 compounds on the active transport mediated by three ABC transporters: breast cancer resistance protein (BCRP and ABCG2), multidrug-resistance associated protein (MRP2 and ABCC2), and P-glycoprotein (P-gp and ABCB1). Eight compounds were strong inhibitors of all three transporters, while the activity of 36 compounds was transporter-specific. Of the tested compounds, 39, 25, and 11 were considered as strong inhibitors, while 1, 4, and 11 compounds were inactive against BCRP, MRP2, and P-gp, respectively. In addition, six transport-enhancing stimulators were observed for P-gp. In order to understand the observed selectivity, we compared the surface properties of binding cavities in the transporters and performed structure-activity analysis and computational docking of the compounds to known binding sites in the transmembrane domains and nucleotide-binding domains. Based on the results, the studied compounds are more likely to interact with the transmembrane domain than the nucleotide-binding domain. Additionally, the surface properties of the substrate binding site in the transmembrane domains of the three transporters were in line with the observed selectivity. Because of the high activity toward BCRP, we lacked the dynamic range needed to draw conclusions on favorable interactions; however, we identified amino acids in both P-gp and MRP2 that appear to be important for ligand recognition.

摘要

三磷酸腺苷结合盒(ABC)-转运蛋白通过将其底物从许多生理屏障(如血脑屏障、肠、肝和肾)中的细胞泵出,来保护组织。这些底物包括各种内源性代谢物,但此外,ABC 转运蛋白还识别广泛的化合物,因此会影响临床使用的药物及其代谢物的处置和消除。尽管已经知道许多 ABC 转运蛋白抑制剂,但抑制的潜在机制尚未得到很好的描述。本研究的目的是通过研究配体识别的分子基础,加深对转运蛋白抑制的理解。在当前的工作中,我们比较了 44 种化合物对三种 ABC 转运蛋白(乳腺癌耐药蛋白(BCRP 和 ABCG2)、多药耐药相关蛋白(MRP2 和 ABCC2)和 P-糖蛋白(P-gp 和 ABCB1)介导的主动转运的影响。八种化合物是所有三种转运蛋白的强抑制剂,而 36 种化合物的活性则具有转运蛋白特异性。在测试的化合物中,有 39、25 和 11 种被认为是强抑制剂,而 1、4 和 11 种化合物对 BCRP、MRP2 和 P-gp 分别无活性。此外,还观察到 6 种增强 P-gp 转运的刺激剂。为了理解观察到的选择性,我们比较了转运蛋白结合腔的表面特性,并对化合物进行了结构活性分析和计算对接,以了解它们在跨膜结构域和核苷酸结合结构域中的已知结合位点的情况。基于这些结果,研究的化合物更有可能与跨膜结构域相互作用,而不是与核苷酸结合结构域相互作用。此外,三种转运蛋白的跨膜结构域中底物结合位点的表面特性与观察到的选择性一致。由于对 BCRP 的高活性,我们缺乏得出有利相互作用结论所需的动态范围;然而,我们确定了 P-gp 和 MRP2 中似乎对配体识别很重要的氨基酸。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/92d6/7497665/5cdf6fcbf26a/mp0c00155_0001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验